ArticleInfectious diseases and therapy2025
Programmatic Assessment of Ethambutol-Related Optic Neuropathy in Patients with Mycobacterial Infections: A Prospective Observational Cohort Study.
Article in Infectious diseases and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Longitudinal Observation by Optical Coherence Tomography in Patients Treated with Ethambutol: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionComprehensive data on ethambutol (EMB)-related optic neuropathy (EON) are lacking, creating a knowledge gap. Accordingly, this prospective programmatic study established a collaborative multidisciplinary team to explore EON.
methodsThis study enrolled patients who received EMB as part of their treatment regimen for mycobacterial infections. Programmatic assessments of visual abnormalities were performed for each patient by the team. EON was diagnosed by ophthalmologists. Patients diagnosed as having EON completed short-term (6-month) and long-term (5-year) follow-up.
resultsOf 476 patients, 31 (6.5%) were diagnosed as having EON. Older age (≥ 65 years, odds ratio [OR] = 2.5, P = 0.043) and diabetes mellitus (OR = 2.2, P = 0.045) were independent predictors of EON, and coexisting subjective and objective ocular abnormalities (OR = 4.8, P = 0.009) and concomitant visual acuity and color discrimination impairment (OR = 5.9, P = 0.009) were independently associated with EON in patients with ocular abnormalities at EMB discontinuation. Among patients with EON, 56.7% and 50.0% had favorable 6-month visual acuity and color discrimination outcomes, respectively. Among patients with unfavorable 6-month visual acuity outcomes, 45.5% had favorable outcomes at the 5-year follow-up. Moreover, 88.2% and 100% of patients with favorable and unfavorable 6-month visual acuity outcomes, respectively, already had these outcomes at the third month of follow-up. Additionally, 50.0% and 100% of patients with favorable and unfavorable 6-month color discrimination outcomes, respectively, already had these outcomes at the fourth month of follow-up.
conclusionsThe incidence of EON exceeded 6%. This study provides a feasible model for the comprehensive management of EON in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.